C-Bridge Capital Leads $150M Round In Merged Chinese Drug Developer

Login to View

C-Bridge Capital, a US$700 million-under-management healthcare private equity fund in China, has teamed up with Tianjin-based traditional Chinese medicine company Tasly Holding Group to invested US$150 million in a newly created Chinese drug developer resulted from a merger of two pharmaceutical firms.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in

China Money Network Subscription